Drugs / PAS-004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06961565 | May 2025 → Sep 2027 expected | neurofibromatosis type 1 due to NF1 mutation or intragenic deletion, plexiform neurofibroma | Pasithea Therapeutics Corp. | Recruiting | No outcome recorded |
| Phase 1 | NCT06299839 | Feb 2024 → Feb 2026 overdue | cancer, neurofibromatosis type 1 | Pasithea Therapeutics Corp. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAS-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961565 ↗ |
| Action | Inhibit | “A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor” NCT06961565 ↗ |
| Route | Oral | “intended for oral administration once daily.” NCT06299839 ↗ |